Addressing challenges of Alzheimer’s therapy and diagnostic value assessment in Europe

416M

people at risk of developing
Alzheimer's disease globally
92%

of neurologists expect blood-based
biomarker tests will increase diagnoses
2 of 27

EU countries have reimbursed
disease-modifying therapies for AD

What is PAVE?

Project Alzheimer's Value Europe (PAVE) is a consortium bringing together key stakeholders across the Alzheimer's ecosystem — including clinicians, patient advocates, health economists, HTA and regulatory experts, and industry — to advance collaboration and enhance value assessment of Alzheimer's therapies and diagnostics in Europe. PAVE leverages European-focused expertise to drive the cross-sector understanding needed to improve access to care.

The breadth of potential interventions, disease complexity, and heterogeneity of the patient population pose significant challenges to the models currently used in value assessment — for both treatments and diagnostics.

Without frameworks that capture the holistic and societal benefits of Alzheimer's therapies and diagnostics, securing access to and funding for future innovations will remain an uphill battle.

BUILDING ON PIAdT

From research to action

PAVE was established to advance the work of the PIAdT Working Group, which identified the core barriers to effective HTA and funding for Alzheimer's innovations in Europe. PIAdT defined the challenges, and PAVE is now working to develop the solutions.

Our Focus Areas

Define Evidence Priorities

Every decision we make is shaped by a clear sense of purpose. Our journey has been anything but ordinary. Through every step, we've focused on staying true to our values and making space for thoughtful, lasting work.

Enable Real-World BBM Implementation

Working with payers and clinicians to address the practical barriers to adopting biomarker-based measures in clinical workflows across Europe.

Build the Case for Delayed Progression

Quantifying the value of slowing Alzheimer's progression in terms patients and payers can act on — time at home, independence, and reduced caregiver burden.

Strengthen Advocacy for Access

Equipping patients, caregivers, and advocacy organizations with the tools and guidance needed to engage effectively in HTA, policy, and reimbursement processes.